Comparison of the efficacy of cisplatin and carboplatin in
combination with etoposide in firstline treatment of
extensive-stage small cell lung cancer in real-world practice
in the Czech Republic - a retrospective analysis of patients
from the LUCAS project

J 2024

Comparison of the efficacy of cisplatin and carboplatin in combination with etoposide in firstline treatment of extensive-stage small cell lung cancer in real-world practice in the Czech Republic - a retrospective analysis of patients from the LUCAS project

BEJCKOVA, Alzbeta, Miloslav MAREL, Zdenka CHLADKOVA, Libor FILA, Luis Fernando CASAS-MENDEZ et. al.

Základní údaje

Originální název

Comparison of the efficacy of cisplatin and carboplatin in combination with etoposide in firstline treatment of extensive-stage small cell lung cancer in real-world practice in the Czech Republic - a retrospective analysis of patients from the LUCAS project

Autoři

Vydání

Biomedical Papers, Olomouc, Palacky University, 2024, 1213-8118

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30203 Respiratory systems

Stát vydavatele

Česká republika

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 0.900 v roce 2022

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.5507/bp.2024.019

UT WoS

001261202100001

Klíčová slova anglicky

small cell lung cancer; extensive-stage; carboplatin; cisplatin

Štítky

14110215

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 12. 7. 2024 10:36, Mgr. Tereza Miškechová

Anotace

V originále

Background. Patients with extensive-stage small-cell lung cancer (ES-SCLC) have a poor prognosis. The standard palliative treatment for four decades has been chemotherapy as a combination of etoposide with carboplatin or cisplatin, and in recent years, immunotherapy in addition. Aims. To determine whether there is a difference in the efficacy of palliative chemotherapy as cisplatin or carboplatin in combination with etoposide in patients with ES-SCLC in real-world practice in the Czech Republic. Methods. This was a retrospective analysis of a cohort of 348 patients from the LUCAS project with ES-SCLC. 79 were treated with etoposide plus cisplatin and 265 were treated with etoposide plus carboplatin. Kaplan-Meier curves and the Cox regression model were used for analysis. Results. No statistically significant difference in median overall survival (mOS) or median progression free survival (mPFS) was found between groups or between patients grouped according to age and performance status (PS) in mOS. The Cox regression result was similar. Conclusion. This study shows that cisplatin and carboplatin do not differ in efficacy in a given indication, thus when choosing a treatment, the physician should consider the expected toxicity in a particular patient, assessing the patient's general condition and comorbidities.

Citovat

BEJCKOVA, Alzbeta, Miloslav MAREL, Zdenka CHLADKOVA, Libor FILA, Luis Fernando CASAS-MENDEZ, Ondřej VENCLÍČEK, Petr JAKUBEC, Marketa CERNOVSKA, Michal HRNCIARIK, Jana KREJCI, Petr DOMECKY a Martin SVATON. Comparison of the efficacy of cisplatin and carboplatin in combination with etoposide in firstline treatment of extensive-stage small cell lung cancer in real-world practice in the Czech Republic - a retrospective analysis of patients from the LUCAS project. Biomedical Papers. Olomouc: Palacky University, 2024, 8 s. ISSN 1213-8118. Dostupné z: https://dx.doi.org/10.5507/bp.2024.019.

@article{2418119,
   author = {Bejckova, Alzbeta and Marel, Miloslav and Chladkova, Zdenka and Fila, Libor and CasasandMendez, Luis Fernando and Venclíček, Ondřej and Jakubec, Petr and Cernovska, Marketa and Hrnciarik, Michal and Krejci, Jana and Domecky, Petr and Svaton, Martin},
   article_location = {Olomouc},
   doi = {http://dx.doi.org/10.5507/bp.2024.019},
   keywords = {small cell lung cancer; extensive-stage; carboplatin; cisplatin},
   language = {eng},
   issn = {1213-8118},
   journal = {Biomedical Papers},
   title = {Comparison of the efficacy of cisplatin and carboplatin in combination with etoposide in firstline treatment of extensive-stage small cell lung cancer in real-world practice in the Czech Republic - a retrospective analysis of patients from the LUCAS project},
   url = {https://biomed.papers.upol.cz/corproof.php?tartkey=bio-000000-3631},
   year = {2024}
}

TY  - JOUR
ID  - 2418119
AU  - Bejckova, Alzbeta - Marel, Miloslav - Chladkova, Zdenka - Fila, Libor - Casas-Mendez, Luis Fernando - Venclíček, Ondřej - Jakubec, Petr - Cernovska, Marketa - Hrnciarik, Michal - Krejci, Jana - Domecky, Petr - Svaton, Martin
PY  - 2024
TI  - Comparison of the efficacy of cisplatin and carboplatin in combination with etoposide in firstline treatment of extensive-stage small cell lung cancer in real-world practice in the Czech Republic - a retrospective analysis of patients from the LUCAS project
JF  - Biomedical Papers
PB  - Palacky University
SN  - 12138118
KW  - small cell lung cancer
KW  - extensive-stage
KW  - carboplatin
KW  - cisplatin
UR  - https://biomed.papers.upol.cz/corproof.php?tartkey=bio-000000-3631
N2  - Background. Patients with extensive-stage small-cell lung cancer (ES-SCLC) have a poor prognosis. The standard palliative treatment for four decades has been chemotherapy as a combination of etoposide with carboplatin or cisplatin, and in recent years, immunotherapy in addition. Aims. To determine whether there is a difference in the efficacy of palliative chemotherapy as cisplatin or carboplatin in combination with etoposide in patients with ES-SCLC in real-world practice in the Czech Republic. Methods. This was a retrospective analysis of a cohort of 348 patients from the LUCAS project with ES-SCLC. 79 were treated with etoposide plus cisplatin and 265 were treated with etoposide plus carboplatin. Kaplan-Meier curves and the Cox regression model were used for analysis. Results. No statistically significant difference in median overall survival (mOS) or median progression free survival (mPFS) was found between groups or between patients grouped according to age and performance status (PS) in mOS. The Cox regression result was similar. Conclusion. This study shows that cisplatin and carboplatin do not differ in efficacy in a given indication, thus when choosing a treatment, the physician should consider the expected toxicity in a particular patient, assessing the patient's general condition and comorbidities.
ER  -

BEJCKOVA, Alzbeta, Miloslav MAREL, Zdenka CHLADKOVA, Libor FILA, Luis Fernando CASAS-MENDEZ, Ondřej VENCLÍČEK, Petr JAKUBEC, Marketa CERNOVSKA, Michal HRNCIARIK, Jana KREJCI, Petr DOMECKY a Martin SVATON. Comparison of the efficacy of cisplatin and carboplatin in combination with etoposide in firstline treatment of extensive-stage small cell lung cancer in real-world practice in the Czech Republic - a retrospective analysis of patients from the LUCAS project. \textit{Biomedical Papers}. Olomouc: Palacky University, 2024, 8 s. ISSN~1213-8118. Dostupné z: https://dx.doi.org/10.5507/bp.2024.019.

Podrobný výpis o publikaci